Retransplantation for hepatitis C-related cirrhosis under long-term pegylated interferon therapy

Area of Science:

• Hepatology
• Transplantation Medicine
• Virology

Background:

• Organ shortage raises ethical questions about retransplantation for hepatitis C virus (HCV)-related graft failure.
• HCV recurrence and graft failure pose significant challenges in liver transplantation.
• Evaluating retransplantation outcomes in HCV patients is crucial for resource allocation.

Purpose of the Study:

• To review the experience with HCV-infected liver transplant recipients undergoing re-orthotopic liver transplantation (OLT).
• To assess the efficacy of prophylactic pegylated interferon and ribavirin in HCV patients post-retransplantation.
• To evaluate graft function and fibrosis progression after re-OLT in HCV-infected recipients.

Main Methods:

• Retrospective review of 5 HCV-infected patients undergoing re-OLT for HCV graft cirrhosis.
• Prophylactic administration of pegylated interferon and ribavirin post-retransplantation.
• Monitoring of graft function, HCV RNA levels, and liver fibrosis progression.

Main Results:

• All 5 patients survived with stable graft function at a median 26-month follow-up.
• Four patients continued prophylactic pegylated interferon for a mean of 20 months.
• Significant reduction in liver fibrosis and slower fibrosis progression observed post-re-OLT.
• HCV RNA levels decreased significantly, although viral clearance was not achieved.

Conclusions:

• Hepatic retransplantation combined with prophylactic antiviral therapy is a viable option for select HCV-infected patients.
• This approach can lead to improved graft function and reduced liver fibrosis progression.
• Further research is warranted to optimize treatment strategies and long-term outcomes.